Carregant...
IL-2, the next best thing in chronic GVHD therapy?
In this issue of Blood, Koreth et al have reported that interleukin-2 (IL-2) is effective in chronic graft-versus-host disease (cGVHD) patients who had failed up to two prior lines of therapy.(1)
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937357/ https://ncbi.nlm.nih.gov/pubmed/27389542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-05-711796 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|